Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033887 | 0.86 | USP2 (0.58) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL2077476 | 0.80 | TSHR (0.55) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL14497716 | 0.80 | USP2 (0.55) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10090160 | 0.78 | MEN1 (0.43) | USP2TSHRMEN1KMT2A | |
| SCHEMBL14280293 | 0.78 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL3147877 | 0.78 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL19450512 | 0.77 | CA2 (0.36) | MEN1KMT2A | |
| SCHEMBL23136970 | 0.76 | ALDH1A1 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL12834941 | 0.74 | MEN1 (0.40) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL23136964 | 0.74 | USP2 (0.48) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3878451-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND | Array Biopharma Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3227297-B1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| CN-107278203-B | 4, 6-substituted pyrazolo [1,5-a ] pyrazines as JANUS kinase inhibitors | 阵列生物制药公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-3110793-B1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3110793-B1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2019-08-21 | — | — | EP | disclosed |
| US-20190177328-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10301256-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-05-28 | — | — | US | disclosed |
| WO-2015079251-A1 | QUINAZOLINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| US-9045400-B2 | Fluorinated aromatic bis(acyl)-containing compounds and polyesters prepared therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-06-02 | — | — | US | disclosed |
| CN-104136441-A | Gonadotropin-releasing hormone receptor antagonists, process for their preparation and pharmaceutical compositions comprising them | SK CHEMICALS CO LTD | 2014-11-05 | — | — | CN | disclosed |
| US-20140200223-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20140163250-A1 | FLUORINATED AROMATIC BIS(ACYL)-CONTAINING COMPOUNDS AND POLYESTERS PREPARED THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| WO-2013129879-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2013-09-06 | — | — | WO | disclosed |
| US-20120071626-A1 | FLUORINATED AROMATIC BIS(ACYL)-CONTAINING COMPOUNDS AND POLYESTERS PREPARED THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2012-03-22 | — | — | US | disclosed |
| US-4524073-A | β-Lactam compounds | BEECHAM GROUP P.1.C. (GB) | 1985-06-18 | — | — | US | disclosed |
| EP-0101199-A1 | Beta-lactam compounds | BEECHAM GROUP PLC (GB) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163250-A1 | FLUORINATED AROMATIC BIS(ACYL)-CONTAINING COMPOUNDS AND POLYESTERS PREPARED THEREFROM | NOTUM, FFAR1, FFAR2 | USP2 2592/4885TSHR 2114/4885KDM4E 2803/4885 |
| US-10301256-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | SULT2A1, FH, STS | USP2 1289/4885TSHR 3365/4885KDM4E 1116/4885 |
| US-20140200223-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | USP2 1715/4885TSHR 4800/4885KDM4E 2509/4885 |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | USP2 3156/4885TSHR 1038/4885KDM4E 726/4885 |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | JAK1, JAK3, JAK2 | USP2 3156/4885TSHR 1038/4885KDM4E 726/4885 |
| US-20190177328-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | USP2 3156/4885TSHR 1038/4885KDM4E 726/4885 |
| US-20120071626-A1 | FLUORINATED AROMATIC BIS(ACYL)-CONTAINING COMPOUNDS AND POLYESTERS PREPARED THEREFROM | AFF1, AFF2, FFAR2 | USP2 1469/4885TSHR 777/4885KDM4E 3292/4885 |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | USP2 3156/4885TSHR 1038/4885KDM4E 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.